Interfacial/foaming properties and antioxidant activity of a silkworm (Bombyx mori) pupae protein concentrate

The current consumer demand for healthier diets, the growing interest in the search for new sources of protein, and the desire to reduce the negative effects on the environment have increased interest in the study of insect proteins. The present study focused on the technofunctional characteristics (interfacial and foaming properties) and the in-vitro antioxidant activity of a protein concentrate obtained from silkworm (Bombyx mori) pupae (SPC). The isoelectric point of the SPC was close to pH 4.0–5.0 as determined by protein solubility and z potential analysis. Given that the SPC had solubilities of ~50% and z potentials of ~20 mV at pH 2.0 and 8.0, it was decided to further study SPC properties at these pH values. The supernatant obtained after adjustment of SPC to pH 8.0 showed higher (p < 0.05) antioxidant activity than that at pH 2.0 when analysed by the ferric reducing antioxidant power (FRAP) assay (168.0 ± 3.0 V. 43.5 ± 8.1 μmol Trolox Eq. ·g−1 protein). However, no significant differences in antioxidant activity were found between pH 2.0 and 8.0 when using the oxygen radical absorbance capacity (ORAC) assay (1826.0 ± 131.9 vs. 1659.2 ± 46.8 μmol Trolox Eq. g−1 protein). The interfacial properties of SPC were determined at pH 2.0 and 8.0 during protein adsorption and after reaching the pseudo equilibrium state by means of dilatational and interfacial shear rheology following by foaming capacity and stability analyses. Faster adsorption kinetic values were obtained at pH 8 ( Vs. at pH 2.0). However, lower kinetic values at pH 2.0 increased the elastic behaviour of the viscoelastic interfacial film formed (E's ⁓ 30 mN/m at pH 2.0 V. E's ⁓ 20 mN/m at pH 8.0), which can be related with the higher protein sizes found at pH 2.0. These rearrangements of the SPC components appeared to increase its foaming capacity, whereas the foaming capacity of SPC adjusted to pH 8.0 was minimal.University of Seville for the VPPI-US grant (Ref.-II.5)Ministerio de Ciencia, Innovación y Universidades (España) / FEDER RTI2018-097100-B-C2

Estudio de la citotoxicidad de cerámicas biomórficas de SiC recubiertas con vidrio bioactivo

La necesidad de desarrollar nuevos implantes basados en materiales bioactivos que sean capaces de soportar grandes cargas mecánicas ha llevado a la producción de sustratos metálicos recubiertos con cerámicas bioactivas. Recientemente se ha propuesto un dispositivo alternativo que consiste en un sustrato de carburo de silicio (SiC) biomórfico recubierto con vidrio bioactivo, mediante la técnica de Depósito por Láser Pulsado (PLD), y que dispone de la resistencia mecánica adecuada, además de gran ligereza y una porosidad intrínseca muy favorable de cara a la implantación. En este trabajo se presenta un estudio interdisciplinar de este nuevo material centrado en la morfología y porosidad de sustratos de SiC provenientes de diferentes maderas, la bioactividad de los recubrimientos producidos por PLD y en la evaluación in vitro con células de osteosarcoma MG-63 con la que se ha determinado la citotoxicidad de estos materiales y se ha estudiado la influencia de los mismos en la adhesión y la proliferación celular.In the past years there was a need to develop new tough bioactive materials capable to resist high loads when implanted in the body, that led to the production of bioactive coatings on metallic substrates. A new approach, which consists of biomorphic silicon carbide (SiC) coated with bioactive glass by Pulsed Laser Deposition (PLD), was recently presented. This new material joins the high mechanical strength, lightness and porosity of biomorphic SiC and the bioactive properties of PLD glass films. In this work, a multiple evaluation of this new material is presented starting from the biomorphic SiC morphology and porosity, following with the bioactivity in simulated body fluid of the coatings, and ending with a deep in vitro study with MG-63 cells. The citotoxicity of the SiC coated and uncoated and the cell proliferation and attachment were studied

Extensive studies on biomorphic SiC ceramics properties for medical applications

Biomorphic silicon carbide ceramics are light, tough and high-strength materials with interesting biomedical applications. The fabrication method of the biomorphic SiC is based in the infiltration of molten-Si in carbon preforms with open porosity. The final product is a biostructure formed by a tangle of SiC fibers. This innovative process allows the fabrication of complex shapes and the tailoring of SiC ceramics with optimised properties and controllable microstructures that will match the biomechanical requirements of the natural host tissue. An interdisciplinary approach of the biomorphic SiC fabricated from beech, sapelly and eucalyptus is presented. Their mechanical properties, microstructure and chemical composition were evaluated. The biocompatible behaviour of these materials has been tested in vitro

Propagación de plantas de Morus alba var. Criolla con el uso de sistemas de inmersión temporal

The mulberry (Morus alba L.) it is a forage plant of great economic importance. The present work was carried out with the purpose of to in vitro propagate the variety ‘Criolla’ via organogenesis with the use of Temporary Immersion Systems. It were defined the media and culture conditions for the temporary immersion systems. The results demonstrated that it was possible to obtain a high multiplication coefficient of 15.5. The immersion frequency had a significant influence on the evaluated variables. Maximum values were observed in the number of buds, the longitude of the buds and the multiplication coefficient with four immersions per day. The plants in vitro cultivated in temporary immersion systems were established in the acclimatization phase in a substrate compound for 85% worm humus and 15% zeolita. It were superior in the morphological variables evaluated regarding those propagated by the conventional method of stakes.Key words: multiplication coefficient, in vitro plants, morphologic variationsLa morera (Morus alba L.) es una planta forrajera de gran importancia económica. El presente trabajo se realizó con la finalidad de propagar in vitro la variedad ‘Criolla’ vía organogénesis con el uso de Sistemas de Inmersión Temporal. Se definieron los medios y condiciones de cultivo para los sistemas de inmersión temporal y los resultados demostraron que fue posible obtener un coeficiente de multiplicación elevado de 15.5. La frecuencia de inmersión tuvo una influencia significativa sobre las variables evaluadas. Se observaron valores máximos en el número de brotes, la longitud de los brotes y el coeficiente de multiplicación con cuatro inmersiones por día. Las plantas cultivadas in vitro mediante sistemas de inmersión temporal se establecieron en la fase de aclimatización en un sustrato compuesto por 85% humus de lombriz y 15% de zeolita y fueron superiores en las variables morfológicas evaluadas respecto a las propagadas por el método convencional de estacas.Palabras clave: coeficiente de multiplicación, plantas in vitro, variaciones morfológica

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease

BACKGROUND AND AIMS: To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. METHODS: Patients under Remicade® who were in clinical remission with standard dosage at study entry were included. The ''switch cohort'' [SC] comprised patients who made the switch from Remicade® to CT-P13, and the ''non-switch'' cohort [NC] patients remained under Remicade®. RESULTS: A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The median follow-up was 18 months in the SC and 23 months in the NC [p < 0.01]. Twenty-four out of 277 patients relapsed in the NC; the incidence of relapse was 5% per patient-year. The cumulative incidence of relapse was 2% at 6 months and 10% at 24 months in this group. Thirty-eight out of 199 patients relapsed in the SC; the incidence rate of relapse was 14% per patient-year. The cumulative incidence of relapse was 5% at 6 months and 28% at 24 months. In the multivariate analysis, the switch to CT-P13 was associated with a higher risk of relapse (HR = 3.5, 95% confidence interval [CI] = 2-6). Thirteen percent of patients had adverse events in the NC, compared with 6% in the SC [p < 0.05]. CONCLUSIONS: Switching from Remicade® to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. The nocebo effect might have influenced this result. Switching from Remicade® to CT-P13 was safe

Fingerprints as Predictors of Schizophrenia: A Deep Learning Study

Background and hypothesis: The existing developmental bond between fingerprint generation and growth of the central nervous system points to a potential use of fingerprints as risk markers in schizophrenia. However, the high complexity of fingerprints geometrical patterns may require flexible algorithms capable of characterizing such complexity. Study design: Based on an initial sample of scanned fingerprints from 612 patients with a diagnosis of non-affective psychosis and 844 healthy subjects, we have built deep learning classification algorithms based on convolutional neural networks. Previously, the general architecture of the network was chosen from exploratory fittings carried out with an independent fingerprint dataset from the National Institute of Standards and Technology. The network architecture was then applied for building classification algorithms (patients vs controls) based on single fingers and multi-input models. Unbiased estimates of classification accuracy were obtained by applying a 5-fold cross-validation scheme. Study results: The highest level of accuracy from networks based on single fingers was achieved by the right thumb network (weighted validation accuracy = 68%), while the highest accuracy from the multi-input models was attained by the model that simultaneously used images from the left thumb, index and middle fingers (weighted validation accuracy = 70%). Conclusion: Although fitted models were based on data from patients with a well established diagnosis, since fingerprints remain lifelong stable after birth, our results imply that fingerprints may be applied as early predictors of psychosis. Specially, if they are used in high prevalence subpopulations such as those of individuals at high risk for psychosis.This work was supported by several grants funded by the Instituto de Salud Carlos III and the Spanish Ministry of Science and Innovation (co-funded by the European Regional Development Fund/European Social Fund “Investing in your future”): Miguel Servet Research Contract (CPII13/00018 to RS, CPII16/00018 to EP-C, CP20/00072 to MF-V), PFIS Contract (FI19/0352 to MG-R). Research Mobility programme (MV18/00054 to EP-C), Research Projects (PI18/00877 and PI21/00525 to RS). It has also been supported by the Centro de Investigación Biomédica en Red de Salud Mental and the Generalitat de Catalunya: 2014SGR1573 and 2017SGR1365 to EP-C and SLT008/18/00206 to IF-R from the Departament de Salut. The authors have declared that there are no conflicts of interest in relation to the subject of this study.S

High expression of antiviral proteins in mucosa from individuals exhibiting resistance to human immunodeficiency virus

ABSTARCT: Several soluble factors have been reported to have the capacity of inhibiting HIV replication at different steps of the virus life cycle, without eliminating infected cells and through enhancement of specific cellular mechanisms. Yet, it is unclear if these antiviral factors play a role in the protection from HIV infection or in the control of viral replication. Here we evaluated two cohorts: i) one of 58 HIV-exposed seronegative individuals (HESNs) who were compared with 59 healthy controls (HCs), and ii) another of 13 HIV-controllers who were compared with 20 HIV-progressors. Peripheral blood, oral and genital mucosa and gut-associated lymphoid tissue (GALT) samples were obtained to analyze the mRNA expression of ELAFIN, APOBEC3G, SAMHD1, TRIM5α, RNase 7 and SerpinA1 using real-time PCR. RESULTS: HESNs exhibited higher expression of all antiviral factors in peripheral blood mononuclear cells (PBMCs), oral or genital mucosa when compared with HCs. Furthermore, HIV-controllers exhibited higher levels of SerpinA1 in GALT. CONCLUSIONS: These findings suggest that the activity of these factors is compartmentalized and that these proteins have a predominant role depending on the tissue to avoid the infection, reduce the viral load and modulate the susceptibility to HIV infection

Neural fuzzy model applied to autohydrolysis of Paulownia trihybrid

A central composite factorial design was used in conjunction with the software ANFIS Edit MATLAB 6.5 to develop fuzzy neural model that reproduced the experimental results of the dependent variables with errors less than 6%. The model is therefore effective with a view to simulating the autohydrolysis process. In this study it was evaluated the potential of a species trihybrid Paulownia fortunei, tormentosa and elongata as an industrial crop in terms of its contents in holocellulose, lignin, xylo-oligomers, monomers and other glucan and its use for making cellulose pulp. It was optimized biomass autohydrolysis processes to obtain valuable liquid and solid phases that can be used to produce liquid fuels and cellulosic pulp. The process was modelled in order to optimize the extraction of xylo-oligomers and xylose in the liquid phase while preserving the integrity of cellulose fibres.The authors acknowledge financial support from the Grupo Empresarial ENCE, S.A. (San Juan delPuerto factory, Huelva, Spain) and VICIDEX EUROPA S.L., and the CICYT-FEDER (Science and Technology Inter Ministerial Commission, Spanish Government European Regional Development Fund), projects numbers CTQ2006-10329/PPQ and AGL2009-13113 for their support, and to the "Ramon y Cajal", "Juan de la Cierva" and FPU Programs of the Spanish Ministry of Science and Innovation

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Background: Patients with inflammatory bowel disease who achieve remission with anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled data investigating this strategy. The primary study aim is to compare the rates of clinical remission at 1?year in patients who discontinue anti-TNF treatment versus those who continue treatment. Methods: This is an ongoing, prospective, double-blind, multicentre, randomized, placebo-controlled study in patients with Crohn?s disease or ulcerative colitis who have achieved clinical remission for ?6?months with an anti-TNF treatment and an immunosuppressant. Patients are being randomized 1:1 to discontinue anti-TNF therapy or continue therapy. Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion. The primary endpoint of the study is sustained clinical remission at 1?year. Other endpoints include endoscopic and radiological activity, patient-reported outcomes (quality of life, work productivity), safety and predictive factors for relapse. The required sample size is 194 patients. In addition to the main analysis (discontinuation versus continuation), subanalyses will include stratification by type of inflammatory bowel disease, phenotype and previous treatment. Biological samples will be obtained to identify factors predictive of relapse after treatment withdrawal. Results: Enrolment began in 2016, and the study is expected to end in 2020. Conclusions: This study will contribute prospective, controlled data on outcomes and predictors of relapse in patients with inflammatory bowel disease after withdrawal of anti-TNF agents following achievement of clinical remission. Clinical trial reference number: EudraCT 2015-001410-1